This inventor holds 1 USPTO granted patent. Top assignee: Licentia, Ltd.. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Innovations by Stenman Ulf-Hakan in Prostate Cancer Research
Introduction
Stenman Ulf-Hakan is a notable inventor based in Kauniainen, Finland. He has made significant contributions to the field of medical research, particularly in the area of prostate cancer diagnostics and treatment. His work focuses on the development of novel peptide ligands that enhance the enzyme activity of prostate-specific antigen (PSA).
Latest Patents
Stenman holds a patent for "Peptide ligands for prostate specific antigen." This invention relates to innovative peptide ligands that bind specifically to PSA, enhancing its enzyme activity. The patent also covers the preparation process for these peptides, as well as their use in diagnostic and pharmaceutical compositions. These peptides are utilized in various methods for determining the concentrations of different molecular forms of PSA and for modulating PSA enzyme activity in both in vivo and in vitro settings.
Career Highlights
Stenman is associated with Licentia Ltd., where he continues to advance his research in peptide ligands. His work has the potential to significantly impact the diagnosis and treatment of prostate cancer, providing new avenues for research and clinical applications.
Collaborations
Stenman has collaborated with notable colleagues, including Ale Närvänen and Erkki Koivunen. These partnerships have contributed to the development and refinement of his innovative research.
Conclusion
Stenman Ulf-Hakan's contributions to prostate cancer research through his patented innovations highlight the importance of peptide ligands in enhancing PSA activity. His work represents a significant advancement in the field, with the potential to improve diagnostic and therapeutic strategies for prostate cancer.